Laurence L Greenhill1, James M Swanson2, Lily Hechtman3, James Waxmonsky4, L Eugene Arnold5, Brooke S G Molina6, Stephen P Hinshaw7, Peter S Jensen8, Howard B Abikoff9, Timothy Wigal10, Annamarie Stehli11, Andrea Howard12, Michael Hermanussen13, Tomasz Hanć14. 1. Division of Child Psychiatry, New York State Psychiatric Institute, and Columbia University, New York, NY. Electronic address: larrylgreenhill@gmail.com. 2. School of Medicine, University of California, Irvine. 3. Division of Child Psychiatry, McGill University, Montreal Children's Hospital, Montreal, Quebec, Canada. 4. Pennsylvania State University Division of Child and Adolescent Psychiatry, Centre County. 5. Ohio State University, Nisonger Center, Columbus. 6. University of Pittsburgh School of Medicine, Pennsylvania. 7. University of California, Berkeley, and the University of California, San Francisco. 8. University of Arkansas for Medical Sciences, Little Rock, and The REACH Institute, New York, NY. 9. Division of Child Psychiatry, New York State Psychiatric Institute, and Columbia University, New York, NY. 10. Clinical Services for Avida Inc., Newport Beach, California. 11. University of California, Irvine. 12. Carleton University, Ottawa, Ontario, Canada. 13. University of Kiel, Kiel, Germany. 14. Adam Mickiewicz University, Poznan, Poland.
Abstract
OBJECTIVE: To estimate long-term stimulant treatment associations on standardized height, weight, and body mass index trajectories from childhood to adulthood in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (MTA). METHOD: Of 579 children with DSM-IV ADHD-combined type at baseline (aged 7.0-9.9 years) and 289 classmates (local normative comparison group [LNCG]), 568 and 258 respectively, were assessed 8 times over 16 years (final mean age = 24.7). Parent interview data established subgroups with self-selected Consistent (n = 53, 9%), Inconsistent (n = 374, 66%), and Negligible (n = 141, 25%) stimulant medication use, as well as patients starting stimulants prior to MTA entry (n = 211, 39%). Height and weight growth trajectories were calculated for each subgroup. RESULTS: Height z scores trajectories differed among subgroups (F = 2.22, p < .0001) and by stimulant use prior to study entry (F = 2.22, p < .001). The subgroup-by-assessment interaction was significant (F = 2.81, p < .0001). Paired comparisons revealed significant subgroup differences at endpoint: Consistent was shorter than Negligible (-0.66 z units /-4.06 cm /1.6 inches, t = -3.17, p < 0.0016), Consistent shorter than Inconsistent (-0.45 z units /-2.74 cm /-1.08 inches, t = -2.39, p < .0172), and the Consistent shorter than LNCG (-0.54 z units/+3.34 cm/ 1.31 inches, t = -3.30, p < 0.001). Weight z scores initially diverged among subgroups, converged in adolescence, and then diverged again in adulthood when the Consistent outweighed the LNCG (+ 3.561 z units /+7.47 kg /+16.46 lb, p < .0001). CONCLUSION: Compared with those negligibly medicated and the LNCG, 16 years of consistent stimulant treatment of children with ADHD in the MTA was associated with changes in height trajectory, a reduction in adult height, and an increase in weight and body mass index. CLINICAL TRIAL REGISTRATION INFORMATION: Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA); https://clinicaltrials.gov/; NCT00000388.
OBJECTIVE: To estimate long-term stimulant treatment associations on standardized height, weight, and body mass index trajectories from childhood to adulthood in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (MTA). METHOD: Of 579 children with DSM-IV ADHD-combined type at baseline (aged 7.0-9.9 years) and 289 classmates (local normative comparison group [LNCG]), 568 and 258 respectively, were assessed 8 times over 16 years (final mean age = 24.7). Parent interview data established subgroups with self-selected Consistent (n = 53, 9%), Inconsistent (n = 374, 66%), and Negligible (n = 141, 25%) stimulant medication use, as well as patients starting stimulants prior to MTA entry (n = 211, 39%). Height and weight growth trajectories were calculated for each subgroup. RESULTS: Height z scores trajectories differed among subgroups (F = 2.22, p < .0001) and by stimulant use prior to study entry (F = 2.22, p < .001). The subgroup-by-assessment interaction was significant (F = 2.81, p < .0001). Paired comparisons revealed significant subgroup differences at endpoint: Consistent was shorter than Negligible (-0.66 z units /-4.06 cm /1.6 inches, t = -3.17, p < 0.0016), Consistent shorter than Inconsistent (-0.45 z units /-2.74 cm /-1.08 inches, t = -2.39, p < .0172), and the Consistent shorter than LNCG (-0.54 z units/+3.34 cm/ 1.31 inches, t = -3.30, p < 0.001). Weight z scores initially diverged among subgroups, converged in adolescence, and then diverged again in adulthood when the Consistent outweighed the LNCG (+ 3.561 z units /+7.47 kg /+16.46 lb, p < .0001). CONCLUSION: Compared with those negligibly medicated and the LNCG, 16 years of consistent stimulant treatment of children with ADHD in the MTA was associated with changes in height trajectory, a reduction in adult height, and an increase in weight and body mass index. CLINICAL TRIAL REGISTRATION INFORMATION: Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA); https://clinicaltrials.gov/; NCT00000388.
Authors: Samuele Cortese; Carlos Renato Moreira-Maia; Diane St Fleur; Carmen Morcillo-Peñalver; Luis Augusto Rohde; Stephen V Faraone Journal: Am J Psychiatry Date: 2015-08-28 Impact factor: 18.112
Authors: T J Spencer; J Biederman; M Harding; D O'Donnell; S V Faraone; T E Wilens Journal: J Am Acad Child Adolesc Psychiatry Date: 1996-11 Impact factor: 8.829
Authors: Elizabeth B Harstad; Amy L Weaver; Slavica K Katusic; Robert C Colligan; Seema Kumar; Eugenia Chan; Robert G Voigt; William J Barbaresi Journal: Pediatrics Date: 2014-09-01 Impact factor: 7.124
Authors: James M Swanson; L Eugene Arnold; Brooke S G Molina; Margaret H Sibley; Lily T Hechtman; Stephen P Hinshaw; Howard B Abikoff; Annamarie Stehli; Elizabeth B Owens; John T Mitchell; Quyen Nichols; Andrea Howard; Laurence L Greenhill; Betsy Hoza; Jeffrey H Newcorn; Peter S Jensen; Benedetto Vitiello; Timothy Wigal; Jeffery N Epstein; Leanne Tamm; Kimberly D Lakes; James Waxmonsky; Marc Lerner; Joy Etcovitch; Desiree W Murray; Maximilian Muenke; Maria T Acosta; Mauricio Arcos-Burgos; William E Pelham; Helena C Kraemer Journal: J Child Psychol Psychiatry Date: 2017-03-10 Impact factor: 8.982
Authors: Peter S Jensen; Kimberly Eaton Hoagwood; Margaret Roper; L Eugene Arnold; Carol Odbert; Maura Crowe; Brooke S G Molina; Lily Hechtman; Stephen P Hinshaw; Betsy Hoza; Jeffrey Newcorn; James Swanson; Karen Wells Journal: J Am Acad Child Adolesc Psychiatry Date: 2004-11 Impact factor: 8.829
Authors: Ellen A Fliers; Jan K Buitelaar; Athanasios Maras; Kim Bul; Esther Höhle; Stephen V Faraone; Barbara Franke; Nanda N J Rommelse Journal: J Dev Behav Pediatr Date: 2013-10 Impact factor: 2.225
Authors: Luis C Farhat; José M Flores; Emily Behling; Victor J Avila-Quintero; Adam Lombroso; Samuele Cortese; Guilherme V Polanczyk; Michael H Bloch Journal: Mol Psychiatry Date: 2022-01-14 Impact factor: 13.437
Authors: Raja B Khan; Maha Bano; Fang Wang; Pan Haitao; Anthony Christensen; Jessica Smith; Andrea Simmons; Zsila S Sadighi Journal: Pediatr Blood Cancer Date: 2020-10-13 Impact factor: 3.167
Authors: Jeanette M Johnstone; Irene Hatsu; Gabriella Tost; Priya Srikanth; Leanna P Eiterman; Alisha M Bruton; Hayleigh K Ast; Lisa M Robinette; Madeline M Stern; Elizabeth G Millington; Barbara L Gracious; Andrew J Hughes; Brenda M Y Leung; L Eugene Arnold Journal: J Am Acad Child Adolesc Psychiatry Date: 2021-07-22 Impact factor: 13.113